메뉴 건너뛰기




Volumn 32, Issue 2, 2014, Pages 68-75

Phase i study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; N (4 (3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO) 3 CYANO 7 ETHOXY 6 QUINOLYL) 4 (DIMETHYLAMINO) 2 BUTENAMIDE; N-(4-(3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; QUINOLINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

EID: 84894807977     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.2787     Document Type: Article
Times cited : (171)

References (37)
  • 1
    • 33745727112 scopus 로고    scopus 로고
    • HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
    • Wang SE, Narasanna A, Perez-Torres M, et al: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38, 2006
    • (2006) Cancer Cell , vol.10 , pp. 25-38
    • Wang, S.E.1    Narasanna, A.2    Perez-Torres, M.3
  • 3
    • 33746154236 scopus 로고    scopus 로고
    • Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
    • DOI 10.1158/0008-5472.CAN-06-0971
    • Shimamura T, Ji H, Minami Y, et al: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66:6487-6491, 2006 (Pubitemid 44085601)
    • (2006) Cancer Research , vol.66 , Issue.13 , pp. 6487-6491
    • Shimamura, T.1    Ji, H.2    Minami, Y.3    Thomas, R.K.4    Lowell, A.M.5    Shah, K.6    Greulich, H.7    Glatt, K.A.8    Meyerson, M.9    Shapiro, G.I.10    Wong, K.-K.11
  • 4
    • 0023196582 scopus 로고
    • erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
    • Di Fiore PP, Pierce JH, Kraus MH, et al: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987 (Pubitemid 17095921)
    • (1987) Science , vol.237 , Issue.4811 , pp. 178-182
    • Di, F.P.P.1    Pierce, J.H.2    Kraus, M.H.3
  • 5
    • 0023430930 scopus 로고
    • Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells
    • Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163, 1987
    • (1987) Proc Natl Acad Sci U S A , vol.84 , pp. 7159-7163
    • Hudziak, R.M.1    Schlessinger, J.2    Ullrich, A.3
  • 8
    • 84862914692 scopus 로고    scopus 로고
    • Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    • Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
    • (2012) N Engl J Med , vol.366 , pp. 109-119
    • Baselga, J.1    Cortés, J.2    Kim, S.B.3
  • 9
    • 79955515280 scopus 로고    scopus 로고
    • Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications
    • Garrett JT, Arteaga CL: Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther 11:793-800, 2011
    • (2011) Cancer Biol Ther , vol.11 , pp. 793-800
    • Garrett, J.T.1    Arteaga, C.L.2
  • 10
    • 84655162706 scopus 로고    scopus 로고
    • Treatment of HER2-positive breast cancer: Current status and future perspectives
    • Arteaga CL, Sliwkowski MX, Osborne CK, et al: Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32, 2012
    • (2012) Nat Rev Clin Oncol , vol.9 , pp. 16-32
    • Arteaga, C.L.1    Sliwkowski, M.X.2    Osborne, C.K.3
  • 11
    • 84859627290 scopus 로고    scopus 로고
    • Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
    • Gallardo A, Lerma E, Escuin D, et al: Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:1367-1373, 2012
    • (2012) Br J Cancer , vol.106 , pp. 1367-1373
    • Gallardo, A.1    Lerma, E.2    Escuin, D.3
  • 12
    • 80755127903 scopus 로고    scopus 로고
    • Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer
    • Miller TW, Rexer BN, Garrett JT, et al: Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224, 2011
    • (2011) Breast Cancer Res , vol.13 , pp. 224
    • Miller, T.W.1    Rexer, B.N.2    Garrett, J.T.3
  • 13
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumors
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumors. Nature 490:61-70, 2012
    • (2012) Nature , vol.490 , pp. 61-70
  • 14
    • 4944232647 scopus 로고    scopus 로고
    • Lung cancer: Intragenic ERBB2 kinase mutations in tumours
    • Stephens P, Hunter C, Bignell G, et al: Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526, 2004
    • (2004) Nature , vol.431 , pp. 525-526
    • Stephens, P.1    Hunter, C.2    Bignell, G.3
  • 18
    • 0242442020 scopus 로고    scopus 로고
    • HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of Herceptin
    • Heinmöller P, Gross C, Beyser K, et al: HER2 status in non-small cell lung cancer: Results from patient screening for enrollment to a phase II study of Herceptin. Clin Cancer Res 9:5238-5243, 2003
    • (2003) Clin Cancer Res , vol.9 , pp. 5238-5243
    • Heinmöller, P.1    Gross, C.2    Beyser, K.3
  • 19
    • 0141456467 scopus 로고    scopus 로고
    • HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry
    • Pellegrini C, Falleni M, Marchetti A, et al: HER-2/Neu alterations in non-small cell lung cancer: A comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 9:3645-3652, 2003 (Pubitemid 37169230)
    • (2003) Clinical Cancer Research , vol.9 , Issue.10 I , pp. 3645-3652
    • Pellegrini, C.1    Falleni, M.2    Marchetti, A.3    Cassani, B.4    Miozzo, M.5    Buttitta, F.6    Roncalli, M.7    Coggi, G.8    Bosari, S.9
  • 20
    • 77950497981 scopus 로고    scopus 로고
    • Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
    • Burstein HJ, Sun Y, Dirix LY, et al: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 1301-1307
    • Burstein, H.J.1    Sun, Y.2    Dirix, L.Y.3
  • 21
    • 58849132314 scopus 로고    scopus 로고
    • HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
    • Perera SA, Li D, Shimamura T, et al: HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A 106:474-479, 2009
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 474-479
    • Perera, S.A.1    Li, D.2    Shimamura, T.3
  • 22
    • 84860532107 scopus 로고    scopus 로고
    • Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy
    • García-García C, Ibrahim YH, Serra V, et al: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18:2603-2612, 2012
    • (2012) Clin Cancer Res , vol.18 , pp. 2603-2612
    • García-García, C.1    Ibrahim, Y.H.2    Serra, V.3
  • 23
    • 78651458656 scopus 로고    scopus 로고
    • AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
    • Chandarlapaty S, Sawai A, Scaltriti M, et al: AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71, 2011
    • (2011) Cancer Cell , vol.19 , pp. 58-71
    • Chandarlapaty, S.1    Sawai, A.2    Scaltriti, M.3
  • 24
    • 80655126355 scopus 로고    scopus 로고
    • MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    • Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, et al: MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov 1:248-259, 2011
    • (2011) Cancer Discov , vol.1 , pp. 248-259
    • Rodrik-Outmezguine, V.S.1    Chandarlapaty, S.2    Pagano, N.C.3
  • 25
    • 2942739164 scopus 로고    scopus 로고
    • A non-parametric approach to the design and analysis of two-dimensional dose-finding trials
    • DOI 10.1002/sim.1796
    • Ivanova A, Wang K: A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Stat Med 23:1861-1870, 2004 (Pubitemid 38787088)
    • (2004) Statistics in Medicine , vol.23 , Issue.12 , pp. 1861-1870
    • Ivanova, A.1    Wang, K.2
  • 26
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 27
    • 65249170861 scopus 로고    scopus 로고
    • A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
    • Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558, 2009
    • (2009) Clin Cancer Res , vol.15 , pp. 2552-2558
    • Wong, K.K.1    Fracasso, P.M.2    Bukowski, R.M.3
  • 28
    • 72149105604 scopus 로고    scopus 로고
    • Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series
    • Lunardi G, Armirotti A, Nicodemo M, et al: Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: A case series. Clin Ther 31:1812-1819, 2009
    • (2009) Clin Ther , vol.31 , pp. 1812-1819
    • Lunardi, G.1    Armirotti, A.2    Nicodemo, M.3
  • 30
    • 77954584507 scopus 로고    scopus 로고
    • Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer
    • Sequist LV, Besse B, Lynch TJ, et al: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3076-3083, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 3076-3083
    • Sequist, L.V.1    Besse, B.2    Lynch, T.J.3
  • 32
    • 84905702255 scopus 로고    scopus 로고
    • HER2 mutations in non-small cell lung cancer: Preliminary efficacy of targeted therapy with neratinib + torisel on a phase I trial
    • Presented at the
    • Gandhi L, Butaney M, Shaw A, et al: HER2 mutations in non-small cell lung cancer: Preliminary efficacy of targeted therapy with neratinib + torisel on a phase I trial. Presented at the World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011
    • World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011
    • Gandhi, L.1    Butaney, M.2    Shaw, A.3
  • 33
    • 0041659114 scopus 로고    scopus 로고
    • Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours
    • DOI 10.1046/j.1365-2559.2003.01663.x
    • Pan CC, Chen PC, Wang LS, et al: Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 43:165-172, 2003 (Pubitemid 36963161)
    • (2003) Histopathology , vol.43 , Issue.2 , pp. 165-172
    • Pan, C.-C.1    Chen, P.C.-H.2    Wang, L.-S.3    Lee, J.-Y.4    Chiang, H.5
  • 34
    • 80051743870 scopus 로고    scopus 로고
    • Urothelial carcinomas: A focus on human epidermal receptors signaling
    • Grivas PD, Day M, Hussain M: Urothelial carcinomas: A focus on human epidermal receptors signaling. Am J Transl Res 3:362-373, 2011
    • (2011) Am J Transl Res , vol.3 , pp. 362-373
    • Grivas, P.D.1    Day, M.2    Hussain, M.3
  • 35
    • 79959790567 scopus 로고    scopus 로고
    • Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues
    • Lammers RJ, Witjes JA: Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther 11:853-858, 2011
    • (2011) Expert Rev Anticancer Ther , vol.11 , pp. 853-858
    • Lammers, R.J.1    Witjes, J.A.2
  • 37
    • 84905702257 scopus 로고    scopus 로고
    • Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    • Presented at the
    • Gajria D, King T, Pannu H, et al: Combined Inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012
    • San Antonio Breast Cancer Symposium, San Antonio, TX, December 4-8, 2012
    • Gajria, D.1    King, T.2    Pannu, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.